XXXX ligand 1 and 2 are highly expressed in @entity189 of the lung: Comparison of @entity3909 areas.

@entity4634 @entity1 @entity146 @entity5 @entity1149 @entity189 @entity3909 @entity1358 @entity8395 @entity405 @entity14797
UNASSIGNED: @entity189 ( @entity189 ) of the lung is a rare type of poorly differentiated @entity1149 ( @entity1149 ) that belongs to @entity189 ( @entity189 ). It exhibits @entity146 and resistance to chemotherapy and radiotherapy. Recently, immunotherapy targeting the @entity8395 ( @entity8395 )/PD ligand 1 ( @entity4634 ) pathway has demonstrated favourable clinical outcomes in @entity1149 . However, the expression patterns of @entity8395 -related molecules in pulmonary @entity189 remain elusive. @entity4634 and @entity14797 expression was estimated in 41 cases of @entity189 using immunohistochemistry. @entity405 (+) and @entity8395 (+) @entity5 -infiltrating lymphocytes (TILs) were also evaluated. @entity4634 and @entity14797 were highly expressed in pulmonary PCs (90.2% [37/41)]; 87.8% [36/41]). The amount of @entity405 (+) or @entity8395 (+) TILs and the ratio of @entity8395 (+)/ @entity405 (+) TILs in @entity189 were higher in males, smokers and older @entity1 . @entity4634 -positive PCs were infiltrated by higher numbers of @entity405 (+) TILs compared to @entity4634 -negative cases (P=0.006). Of note, @entity4634 expression in pulmonary PCs was significantly higher in sarcomatous areas than in the @entity3909 portion (P=0.006). @entity189 @entity1 with a high ratio of @entity8395 (+)/ @entity405 (+) TILs showed a shorter progression-free survival (P=0.036), whereas @entity4634 and @entity14797 expression had no prognostic implications. Our study demonstrates that pulmonary PCs very frequently express @entity4634 and @entity14797 . Moreover, their expression is higher in @entity1358 areas. Thus, targeting the @entity8395 / @entity4634 pathway may represent a potential therapeutic candidate for this @entity5 .
